Show simple item record

Risk factors for recurrent C lostridium difficile infection in hematopoietic stem cell transplant recipients

dc.contributor.authorHuang, A.M.en_US
dc.contributor.authorMarini, B.L.en_US
dc.contributor.authorFrame, D.en_US
dc.contributor.authorAronoff, D.M.en_US
dc.contributor.authorNagel, J.L.en_US
dc.date.accessioned2014-11-04T16:35:13Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-11-04T16:35:13Z
dc.date.issued2014-10en_US
dc.identifier.citationHuang, A.M.; Marini, B.L.; Frame, D.; Aronoff, D.M.; Nagel, J.L. (2014). "Risk factors for recurrent C lostridium difficile infection in hematopoietic stem cell transplant recipients." Transplant Infectious Disease 16(5): 744-750.en_US
dc.identifier.issn1398-2273en_US
dc.identifier.issn1399-3062en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109272
dc.description.abstractBackground Recurrent C lostridium difficile infection ( CDI ) represents a significant burden on the healthcare system and is associated with poor outcomes in hematopoietic stem cell transplant ( HSCT ) patients. Data are limited evaluating recurrence rates and risk factors for recurrence in HSCT patients. Methods HSCT patients who developed CDI between January 2010 and December 2012 were divided into 2 groups: non‐recurrent CDI (nr CDI ) and recurrent CDI ( rCDI ). Risk factors for rCDI were compared between groups. Rate of recurrence in HSCT patients was compared to that in other hospitalized patients. Results CDI was diagnosed in 95 of 711 HSCT patients (22 rCDI and 73 nr CDI ). Recurrence rates were similar in HSCT patients compared with other hospitalized patients (23.2% vs. 22.9%, P  > 0.99). Patients in the rCDI group developed the index case of CDI significantly earlier than the nr CDI group (3.5 days vs. 7.0 days after transplant, P  = 0.05). On univariate analysis, patients with rCDI were more likely to have prior history of CDI and neutropenia at the time of the index CDI case. Neutropenia at the time of the index CDI case was the only independent predictor of rCDI (78.8 vs. 34.8%, P  = 0.006) on multivariate analysis. Conclusions The rate of rCDI was similar between HSCT and other hospitalized patients, and the majority of patients developed the index case of CDI within a week of transplantation. Neutropenia at the index CDI case may be associated with increased rates of rCDI .en_US
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherRecurrenceen_US
dc.subject.otherRecurrent C Lostridium Difficileen_US
dc.subject.otherStem Cell Transplanten_US
dc.titleRisk factors for recurrent C lostridium difficile infection in hematopoietic stem cell transplant recipientsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelMedicine (General)en_US
dc.subject.hlbsecondlevelMicrobiology and Immunologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109272/1/tid12267.pdf
dc.identifier.doi10.1111/tid.12267en_US
dc.identifier.sourceTransplant Infectious Diseaseen_US
dc.identifier.citedreferenceMcDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile‐ associated disease. Infect Control Hosp Epidemiol 2007; 28: 140 – 145.en_US
dc.identifier.citedreferenceChakrabarti S, Lees A, Jones SG, Milligan DW. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft‐versus‐host disease and non‐relapse‐mortality. Bone Marrow Transplant 2000; 26 ( 8 ): 871 – 876.en_US
dc.identifier.citedreferenceDubberke ER, Reske KA, Srivastava A, et al. Clostridium difficile ‐associated disease in allogeneic hematopoietic stem‐cell transplant recipients: risk associations, protective associations, and outcomes. Clin Transplant 2010; 24: 192 – 198.en_US
dc.identifier.citedreferenceWillems L, Porcher R, Lafaurie M, et al. Clostridium difficile infection after allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 2012; 18: 1295 – 1301.en_US
dc.identifier.citedreferenceLeung S, Metzger BS, Currie BP. Incidence of Clostridium difficile infection in patients with acute leukemia and lymphoma after allogeneic hematopoietic stem cell transplantation. Infect Control Hosp Epidemiol 2010; 31: 313 – 315.en_US
dc.identifier.citedreferenceTrifilio SM, Pi J, Mehta J. Changing epidemiology of Clostridium difficile ‐associated disease during stem cell transplantation. Biol Blood Marrow Transplant 2013; 19 ( 3 ): 405 – 409. Epub 2012 Dec 4.en_US
dc.identifier.citedreferenceAlonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of Clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2012; 54 ( 8 ): 1053 – 1063.en_US
dc.identifier.citedreferenceEyre DW, Walker AS, Wyllie D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012; 55 ( S2 ): S77 – S787.en_US
dc.identifier.citedreferenceGlucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft‐versus‐host disease in human recipients of marrow from HL‐A‐matched sibling donors. Transplantation 1974; 18: 295 – 304.en_US
dc.identifier.citedreferenceBabakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Soneshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55 ( S2 ): S162 – S169.en_US
dc.identifier.citedreferenceBodet CA 3rd, Jorgensen JH, Drutz DJ. Antibacterial activities of antineoplastic agents. Antimicrob Agents Chemother 1985; 28 ( 3 ): 437 – 439.en_US
dc.identifier.citedreferenceStringer AM, Gibson RJ, Bowen JM, Keefe DMK. Chemotherapy‐induced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009; 10 ( 1 ): 79 – 83.en_US
dc.identifier.citedreferenceBacon AE 3rd, Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic‐associated diarrhea. Diagn Microbiol Infect Dis 1994; 18: 205 – 209.en_US
dc.identifier.citedreferenceWarny M, Vaerman JP, Avesani V, Delmee M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384 – 389.en_US
dc.identifier.citedreferenceLeung DY, Kelly CP, Boguniewics M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 18: 633 – 637.en_US
dc.identifier.citedreferenceKyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189 – 193.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.